Ascendis Pharma A/S (ASND)
226.36
+3.23
(+1.45%)
USD |
NASDAQ |
Sep 24, 11:29
Ascendis Pharma Cash from Operations (TTM) : 405.71M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 405.71M |
| March 31, 2026 | 68.72M |
| December 31, 2025 | 62.69M |
| September 30, 2025 | -108.86M |
| June 30, 2025 | -171.97M |
| March 31, 2025 | -228.18M |
| December 31, 2024 | -323.37M |
| September 30, 2024 | -276.98M |
| June 30, 2024 | -352.63M |
| March 31, 2024 | -454.42M |
| December 31, 2023 | -501.94M |
| September 30, 2023 | -602.42M |
| June 30, 2023 | -562.81M |
| March 31, 2023 | -528.13M |
| December 31, 2022 | -517.08M |
| September 30, 2022 | -518.68M |
| June 30, 2022 | -536.68M |
| March 31, 2022 | -542.60M |
| December 31, 2021 | -494.19M |
| September 30, 2021 | -458.60M |
| June 30, 2021 | -410.66M |
| March 31, 2021 | -334.29M |
| December 31, 2020 | -309.56M |
| September 30, 2020 | -257.79M |
| June 30, 2020 | -257.44M |
| Date | Value |
|---|---|
| March 31, 2020 | -201.08M |
| December 31, 2019 | -196.92M |
| September 30, 2019 | -183.86M |
| June 30, 2019 | -171.11M |
| March 31, 2019 | -188.72M |
| December 31, 2018 | -164.46M |
| September 30, 2018 | -152.50M |
| June 30, 2018 | -127.87M |
| March 31, 2018 | -129.93M |
| December 31, 2017 | -107.33M |
| September 30, 2017 | -96.60M |
| June 30, 2017 | -84.17M |
| March 31, 2017 | -73.16M |
| December 31, 2016 | -67.00M |
| September 30, 2016 | -59.50M |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | -24.41M |
| September 30, 2014 | -18.30M |
| June 30, 2014 | 0.3944M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| BioMarin Pharmaceutical, Inc. | 857.09M |
| Novo Nordisk A/S | 20.59B |
| Evaxion AS | -- |
| Genmab A/S | 891.90M |
| Zealand Pharma A/S | -241.46M |